[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
15
Ṁ24602030
1D
1W
1M
ALL
36%
2030
28%
2029
21%
2028
20%
2027
16%
2026
14%
2025
Inspired by https://manifold.markets/AaronKaufman/will-any-fdaapproved-glp1-agonists and will use the same criteria:
GLP-1 agonists, such as semaglutide (ozempic/wegovy), tirzepatide (mounjaro), and dulaglutide (Trulicity), are becoming popular for weight loss and Type-2 diabetes treatment.
This market resolves positively if any approved GLP-1 agonists for either T2D or weight loss are withdrawn from the market due to safety reasons by the listed date. This applies either if the FDA mandates it or if the company withdraws the drug voluntarily.
Get Ṁ1,000 play money
Related questions
Related questions
Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?
14% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
33% chance
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will Donald Trump ever take a GLP-1 agonist (eg Ozempic, Mounjaro, Wegovy, Zepbound, etc) for weight loss
65% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
75% chance
Will aducanumab be withdrawn by the FDA by 2025?
47% chance
Reliable Reporting indicating that more than 3% of Americans are taking GLP-1 agonists in 2024
36% chance
Will a clinical trial reporting weight-loss benefits of a GLP-1 agonist be published in a major medical journal in 2024?
83% chance
What fraction of US adults will regularly take GLP-1 drugs in 2030?
Will there be medical consensus that GLP-1 drugs have cardiovascular benefits beyond those provided via weight loss?
71% chance